This notification is to inform you of point-of-sale (POS) drug utilization review (DUR) edits for opioids that will be enforced for all Commercial plans that process claims through EnvisionRxOptions (“Envision”) effective December 18, 2017.

The below sheets describe each edit in detail and the associated steps needed to properly evaluate and/or adjudicate opioid claims and their rejections as they may arise.

Should you have any questions, please contact our Customer Care Center at 1-800-361-4542.

Sincerely,

EnvisionRxOptions